No Data
Abbisko Doses First Gastric Cancer Patient in Phase II Study of Solid Tumor Drug
Hoi-B (02256.HK): The first dose of the II phase clinical trial of oral PD-L1 small molecule inhibitor ABSK043 combined with FGFR2/3 small molecule inhibitor ABSK061 for the treatment of solid tumors was administered to a gastric cancer patient.
On November 22, 2023, Gelonghui announced that He Yu-B (02256.HK) completed the administration to the first gastric cancer patient in the "open-label multicenter phase II clinical study (protocol number: ABSK061-201) evaluating the safety and efficacy of ABSK061 and ABSK043 alone or in combination with chemotherapy in patients with FGFR2/3 altered metastatic/unresectable solid tumors."
HK stocks anomaly | Hoyo-B (02256) now up more than 4%. The results of the Phase III clinical trial of Pembrolizumab are announced. If Merck chooses to exercise the option, it will enhance the company's performance.
Glory-B (02256) rose more than 8% intraday, as of the time of publication, it increased by 4.15%, closing at 4.27 Hong Kong dollars, with a turnover of 6.335 million Hong Kong dollars.
Wuho-B (02256.HK) presented the dose selection study results guided by the Pimtini model at the 2024 ACoP conference.
On November 13, Gloncyber reported that Hoyo-B (02256.HK) issued an announcement. The company's subsidiary Shanghai Hoyo Biomedical Technology Co., Ltd. ("Hoyo Medicine") showcased its independently developed oral, highly selective, active CSF-1R small molecule inhibitor, Piminterini (ABSK021), for the treatment of tenosynovial giant cell tumor ("TGCT") at the 2024 American Quantitative Pharmacology Conference ("2024 ACoP Conference"). The research presented this time integrates drug metabolism kinetics, safety, and efficacy information for dose selection guided by the model.
Express News | Pimicotinib Significantly Improved Outcomes for Patients With Tenosynovial Giant Cell Tumor in a Global Phase III Trial
Hutchmed-B (02256.HK): Positive top-line results from the pivotal Phase 3 MANEUVER study of pexidartinib in treating TGCT patients, as well as the latest Phase 1 study results of pexidartinib in treating TGCT patients.
Gelonghui November 12th ∣ Hoyou-B (02256.HK) announced that on November 12, 2024, its subsidiary shanghai Hoyou Biomedical Technology Co., Ltd. ("Hoyou Biomedical") announced that the CSF-1R small molecule inhibitor Pimetryn, independently developed by Hoyou Biomedical, has achieved positive top-line results in the pivotal phase 3 MANEUVER study for the treatment of tenosynovial giant cell tumor (TGCT) patients, as well as the latest phase 1 study results for Pimetryn in treating TGCT.
No Data
No Data